SBIR PHASE I - TOPIC 405 - PROJECT TITLE: IN VIVO PHARMACOTYPING OF COMBINATION THERAPY IN PRIMARY BRAIN TUMORSFIRM FIXED PRICE - POP: 09/16/2020 - 0

SBIR 第一阶段 - 主题 405 - 项目名称：原发性脑肿瘤联合疗法的体内药型确定固定价格 - POP：09/16/2020 - 0

• 批准号: 10280953
• 负责人: CHRISTIAN KNOOPKE
• 金额: $ 40万
• 依托单位: LODESTONE BIOMEDICAL, LLC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-16 至 2021-06-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10280953
• 关键词: Binding; Biological Models; Biosensor; Brain; Brain Glioblastoma; Brain Neoplasms; Cells; Combined Modality Therapy; Confidence Intervals; Devices; Enzyme-Linked Immunosorbent Assay; FDA approved; Glioblastoma; Immunocompetent; Immunotherapy; In Vitro; Investigation; MGMT gene; Magnetic nanoparticles; Measurement; Microdialysis; Modeling; Monitor; Mus; Oncogenic; Patients; Performance; Phase; Phenotype; Price; Primary Neoplasm; Procedures; Quality Control; Resistance; Safety; Small Business Innovation Research Grant; System; Technology; Therapeutic; Time; Tumor-Derived; base; design; immunogenic; in vivo; response; specific biomarkers; targeted biomarker; temozolomide; treatment response; tumor; tumor-immune system interactions

Lodestone Biomedical’s Immunotherapy Response Indication System (IRIS) interrogates the binding states of functionalized magnetic nanoparticles (fMNPs) localized in biosensor probes for direct in vivo longitudinal monitoring of therapeutic responses in the patient tumor immune microenvironment (TIME). Herein, we propose to commercialize the IRIS platform technology for pharmacotyping immunotherapies and temozolomide (TMZ) in glioblastoma multiforme (GBM) brain tumors. IRIS technology offers the potential for direct in vivo pharmacotyping capable of differentiating phenotypic responses across ultimately numerous tumor-derived oncogenic and immunogenic factors. This Phase 1 project directly validates the IRIS platform device measurements of target binding sensitivity to singleplex fMNP pairs in solution vs standard ELISA via Bland-Altman plot analysis, with a go-no-go requirement for >95% CI. The potential for IRIS platform technology will be demonstrated across a restricted subset of target specific biosensors in the well- characterized GBM model system, as well as appropriately pharmacotyping responsiveness to TMZ in more diverse MGMT positive and negative patient derived tumor lines. Finally, preliminary investigations of safety and proof of concept will be demonstrated in real time, localized, in vivo GBM pharmacotyping of combination therapy. Ultimately, IRIS technology will bring reliable indicators of therapeutic responsiveness with a practical implementation to the patient bedside.

Lodestone Biomedical的免疫治疗反应指示系统（IRIS）询问定位在生物传感器探针中的功能化磁性纳米颗粒（fMNPs）的结合状态，用于直接在体内纵向监测患者肿瘤免疫微环境（TIME）中的治疗反应。在此，我们建议将IRIS平台技术商业化，用于多形性胶质母细胞瘤（GBM）脑肿瘤的免疫疗法和替莫唑胺（TMZ）的药物分型。IRIS技术提供了直接体内药物分型的潜力，能够区分最终多种肿瘤源性致癌和免疫原性因素的表型反应。该一期项目通过Bland-Altman图分析，直接验证IRIS平台设备测量的溶液中单路fMNP对与标准ELISA的靶结合灵敏度，要求95% CI为0。IRIS平台技术的潜力将在具有良好特征的GBM模型系统中的有限的目标特异性生物传感器子集中得到证明，以及在更多样化的MGMT阳性和阴性患者衍生肿瘤系中对TMZ的适当药物分型反应性。最后，对安全性和概念验证的初步调查将在联合治疗的实时、局部、体内GBM药物分型中进行演示。最终，IRIS技术将为患者床边带来可靠的治疗反应性指标。